



## Interface Prescribing & New Therapies Subgroup



27<sup>th</sup> September 2011

### **Exenatide once-weekly (Bydureon®) prolonged release injection.**

**The Interface Prescribing and New Therapies Subgroup (IPNTS) discussed the above drug at a meeting on the 24<sup>th</sup> May 2011 and again at its meeting on 27<sup>th</sup> September 2011. The recommendation of this subgroup is as follows:\***

The Interface Prescribing & New Therapies Subgroup of the GMMM considered the use of exenatide once-weekly for the treatment of type 2 diabetes in combination as dual or triple therapy in adults who have not received adequate glycaemic control on maximally tolerated doses of existing therapies.

**The group recommends exenatide once weekly as a potential treatment option for those patients suitable to receive other GLP-1 mimetics as per NICE TA203 and CG87.**

The group noted that data showed that glycaemic control and weight reduction have been maintained with up to 2 years of once-weekly exenatide treatment however no long term safety data or effects on morbidity or mortality (diabetes or other) are currently available.

The cost of once weekly exenatide is comparable with other GLP-1 mimetics. The cost has been set at £73.36 for 4 weekly packs. In comparison liraglutide 1.2m/day was £78.48 per 30 days and exenatide 5 or 10 µg was £68.24 per 30 days. It was however noted that as exenatide was a twice daily preparation and liraglutide a once daily preparation the cost of the needles would also need to be factored in.

According to set criteria exenatide once-weekly was deemed to be a low priority for funding.

Review date: September 2013

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.

NOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES